Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager. Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study.Subject is, or previously has been, receiving cardiac resynchronization therapy.Subject has permanent atrial arrhythmias for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted.Subject is not expected to remain available for at least 2 years of follow-up visits.Subject is less than 18 years of age (or has not reached minimum age per local law).Optimal medical therapy is defined as maximal tolerated dose of Beta-blockers and a therapeutic dose of ACE-I, ARB or Aldosterone Antagonist. NYHA class II, III or IV (documented within 30 days prior to enrollment) despite optimal medical therapy.Left ventricular ejection fraction less than or equal to 35% (documented within 180 days prior to enrollment).Intrinsic, normal AV conduction as documented on an ECG by a PR interval less than or equal to 200ms (within 30 days prior to enrollment).Complete Left Bundle Branch Block (LBBB) as documented on an ECG (within 30 days prior to enrollment).Subject is indicated for a CRT device according to local guidelines.Subject is willing to sign and date the study Patient Informed Consent Form.Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |